• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

    11/13/24 4:21:55 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATXS alert in real time by email
    SC 13G/A 1 d882097dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Astria Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    04635X 10 2

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 04635X 10 2    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover GP II, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,761,861 (1)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,761,861 (1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,761,861 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.9% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    These securities are held of record by TCG Crossover II (as defined in Item 2(a) below). TCG Crossover GP II (as defined in Item 2(a) below) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 56,425,282 shares of Common Stock outstanding as of July 31, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission (the “Commission”) on August 12, 2024 (the “Form 10-Q”).


    CUSIP No. 04635X 10 2    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover Fund II, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,761,861 (1)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,761,861 (1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,761,861 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.9% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 56,425,282 shares of Common Stock of the Issuer outstanding, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 04635X 10 2    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Chen Yu

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,761,861 (1)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,761,861 (1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,761,861 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.9% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 56,425,282 shares of Common Stock of the Issuer outstanding, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 04635X 10 2    13G

    Explanatory Note

    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the Schedule 13G initially filed with the Commission on January 16, 2024 (the “Original Schedule 13G”) and is being filed by TCG Crossover Fund II, L.P. (“TCG Crossover II”) and TCG Crossover GP II, LLC (“TCG Crossover GP II” and together with TCG Crossover II, the “Reporting Entities”) and Chen Yu (the “Reporting Individual”). The Reporting Entities and the Reporting Individual are collectively referred to as the “Reporting Persons.” The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is filed as Exhibit 1 to the Original Schedule 13G. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 1 have the meanings ascribed to them in the Original Schedule 13G.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    22 Boston Wharf Road, 10th Floor

    Boston, MA 02210

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (b)

    Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (ii)

    Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iii)

    Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iv)

    Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5% of the class of securities, check the following: ☒


    CUSIP No. 04635X 10 2    13G

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 13, 2024

     

    TCG Crossover Fund II, L.P.
    By:   TCG Crossover GP II, LLC
    Its:   General Partner
    By:   /s/ Craig Skaling
      Authorized Signatory
    TCG Crossover GP II, LLC
    By:   /s/ Craig Skaling
      Authorized Signatory
    /s/ Craig Skaling, as attorney-in-fact for Chen Yu
    Chen Yu
    Get the next $ATXS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATXS

    DatePrice TargetRatingAnalyst
    9/17/2025$16.00 → $20.00Buy
    H.C. Wainwright
    4/29/2025$47.00Overweight
    Cantor Fitzgerald
    1/31/2025$26.00Mkt Outperform
    JMP Securities
    7/29/2024$35.00Buy
    TD Cowen
    3/28/2023$18.00Outperform
    Evercore ISI
    9/29/2021$20.00Buy
    Jefferies
    More analyst ratings

    $ATXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Astria Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $20.00 from $16.00 previously

    9/17/25 11:36:24 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Astria Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Astria Therapeutics with a rating of Overweight and set a new price target of $47.00

    4/29/25 8:10:45 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Astria Therapeutics with a new price target

    JMP Securities initiated coverage of Astria Therapeutics with a rating of Mkt Outperform and set a new price target of $26.00

    1/31/25 6:57:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Agarwal Sunil

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    6/12/25 7:16:46 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bate Kenneth

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    6/12/25 7:15:46 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cole Hugh M

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    6/12/25 7:14:39 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perceptive Advisors Llc bought $29,999,522 worth of shares (2,481,350 units at $12.09) (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    2/5/24 5:02:33 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perceptive Advisors Llc bought $4,588,000 worth of shares (740,000 units at $6.20) (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    12/22/23 2:51:57 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perceptive Advisors Llc bought $6,999,997 worth of shares (1,074,608 units at $6.51) (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    10/18/23 4:11:36 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology

    -- Results Support Potential for STAR-0310 to be Best-in-Class OX40 Antagonist -- -- STAR-0310 Exhibits Longest-in-Class Half-Life of 68 Days and Cytokine Suppression Lasting At Least 20 Weeks After a Single 300 mg SC Injection, Supporting Potential Every-Six-Month Administration -- -- STAR-0310 Was Well-Tolerated, with no ADCC-Related Treatment-Emergent Adverse Events, Supporting a Wider Therapeutic Window with the Potential to Drive Greater Efficacy than First-Generation OX40 Antibodies -- -- Results to be Presented by Dr. Stephan Weidinger, M.D., Ph.D. on September 18, at 4:00pm CEST -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing lif

    9/17/25 8:00:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 128,000 shares of Astria's common stock on September 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to three employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.59, which is equal to the closing price of

    9/3/25 4:10:00 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

    Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology & Venereology (EADV) Congress 2025, taking place September 17-20, 2025 in Paris, France. Stephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, will present initial results from the Phase 1a trial of STAR-0310 in healthy participants in a late-breaking oral presentation titled, "Demonstration of Early Proof-of-Conce

    9/3/25 8:00:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Astria Therapeutics Inc.

    SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    8/14/25 5:56:05 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Astria Therapeutics Inc.

    S-8 - Astria Therapeutics, Inc. (0001454789) (Filer)

    8/12/25 4:34:26 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Astria Therapeutics Inc.

    10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)

    8/12/25 4:02:25 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

    SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 5:46:12 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

    SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 5:45:56 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Astria Therapeutics Inc.

    SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 4:41:28 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Leadership Updates

    Live Leadership Updates

    View All

    Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

    Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl

    4/9/24 8:00:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Financials

    Live finance-specific insights

    View All

    Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

    -- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological

    3/25/24 7:30:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th

    Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com, or with the following link: https://lifescievents.com/event/astria-2/. Please connect to the webca

    10/30/23 8:00:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

    -- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-03

    10/11/23 5:10:00 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care